| Dr Christopher Lang Faubel, MD | |
|
650 S Randall Rd, Algonquin, IL 60102-5944 | |
| (815) 398-9491 | |
| (815) 381-7498 |
| Full Name | Dr Christopher Lang Faubel |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 17 Years |
| Location | 650 S Randall Rd, Algonquin, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588855746 | NPI | - | NPPES |
| 1005428 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 036130705 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwestern Medicine Mchenry Hospital | Mchenry, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthomidwest Pllc | 0749183713 | 386 |
News Archive
As Idaho families, businesses and retirees struggle with soaring health care costs, a vague bill aimed at tackling an issue in a non-existent federal health care law could make the crisis worse for many of the state's residents. The Idaho Health Freedom Act (HB 391) is set to be heard by Idaho Senate State Affairs Committee tomorrow morning, and AARP says the legislation is unproven, untried and vague and is urging them to reject the bill.
Halozyme Therapeutics, Inc. today announced that Roche has completed patient enrollment for the pivotal Phase 3 study of Herceptin SC (trastuzumab subcutaneous), a subcutaneous formulation that uses Halozyme's Enhanze™ technology (rHuPH20, recombinant human hyaluronidase).
The GOP is now pressing to suspend visas for some travelers since the administration has so far rejected calls for a flight ban. Also Monday, the Centers for Disease Control and Prevention beefed-up its guidelines to protect health care workers.
Earl L. Smith III, O.D., dean of the College of Optometry and Greeman-Petty Professor at the University of Houston, is the 2010 recipient of the Charles F. Prentice Medal Award from the American Academy of Optometry.
Not enough communication takes place between drug companies and payers before Phase 3, according to a new study from Cutting Edge Information (http://www.cuttingedgeinfo.com/market-access/). The study finds that drug companies contact payers an average 2.4 times in all of Phase 2.
› Verified 5 days ago
| Entity Name | Orthomidwest Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730136474 PECOS PAC ID: 0749183713 Enrollment ID: O20040128000533 |
News Archive
As Idaho families, businesses and retirees struggle with soaring health care costs, a vague bill aimed at tackling an issue in a non-existent federal health care law could make the crisis worse for many of the state's residents. The Idaho Health Freedom Act (HB 391) is set to be heard by Idaho Senate State Affairs Committee tomorrow morning, and AARP says the legislation is unproven, untried and vague and is urging them to reject the bill.
Halozyme Therapeutics, Inc. today announced that Roche has completed patient enrollment for the pivotal Phase 3 study of Herceptin SC (trastuzumab subcutaneous), a subcutaneous formulation that uses Halozyme's Enhanze™ technology (rHuPH20, recombinant human hyaluronidase).
The GOP is now pressing to suspend visas for some travelers since the administration has so far rejected calls for a flight ban. Also Monday, the Centers for Disease Control and Prevention beefed-up its guidelines to protect health care workers.
Earl L. Smith III, O.D., dean of the College of Optometry and Greeman-Petty Professor at the University of Houston, is the 2010 recipient of the Charles F. Prentice Medal Award from the American Academy of Optometry.
Not enough communication takes place between drug companies and payers before Phase 3, according to a new study from Cutting Edge Information (http://www.cuttingedgeinfo.com/market-access/). The study finds that drug companies contact payers an average 2.4 times in all of Phase 2.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Lang Faubel, MD Po Box 735263, Chicago, IL 60673-5263 Ph: () - | Dr Christopher Lang Faubel, MD 650 S Randall Rd, Algonquin, IL 60102-5944 Ph: (815) 398-9491 |
News Archive
As Idaho families, businesses and retirees struggle with soaring health care costs, a vague bill aimed at tackling an issue in a non-existent federal health care law could make the crisis worse for many of the state's residents. The Idaho Health Freedom Act (HB 391) is set to be heard by Idaho Senate State Affairs Committee tomorrow morning, and AARP says the legislation is unproven, untried and vague and is urging them to reject the bill.
Halozyme Therapeutics, Inc. today announced that Roche has completed patient enrollment for the pivotal Phase 3 study of Herceptin SC (trastuzumab subcutaneous), a subcutaneous formulation that uses Halozyme's Enhanze™ technology (rHuPH20, recombinant human hyaluronidase).
The GOP is now pressing to suspend visas for some travelers since the administration has so far rejected calls for a flight ban. Also Monday, the Centers for Disease Control and Prevention beefed-up its guidelines to protect health care workers.
Earl L. Smith III, O.D., dean of the College of Optometry and Greeman-Petty Professor at the University of Houston, is the 2010 recipient of the Charles F. Prentice Medal Award from the American Academy of Optometry.
Not enough communication takes place between drug companies and payers before Phase 3, according to a new study from Cutting Edge Information (http://www.cuttingedgeinfo.com/market-access/). The study finds that drug companies contact payers an average 2.4 times in all of Phase 2.
› Verified 5 days ago
Kathleen A Ryan Ceisel, PT Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 1213 S Main St, Algonquin, IL 60102 Phone: 224-505-3343 |